Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–45
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Healthy male subject
Age: 18 to 45 years (inclusive) at the first screening examination / visit
Body mass index (BMI): 18 to 32 kg/m² (inclusive)
Ability to understand and follow study-related instructions
Subjects enrolled in this study must use adequate barrier birth control measures prior to, during the course of the study, and 3 months after the last administration of regorafenib. An adequate contraception includes the use of condoms or a vasectomy. In addition, adequate birth control measures for the subject's partner is required, such as a hormonal contraception with implants or combined oral contraceptives, certain intrauterine devices, bilateral tubal ligation, or hysterectomy.
